PYXS: GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D discloses a purchase

By AlphaYouPublished Oct 2, 2026Form 4

Stocks in this disclosure

Reported activity

GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D

Reporting filer

GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D reported Purchase in Pyxis Oncology, Inc.: 5517000 units of Common Stock, par value $0.001 per share ("Common Stock"), dated 2026-10-01. The full Form 4 contains 2 transaction entries.

Disclosed: Oct 2, 2026

Reported details

2 entries

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Common Stock, par value $0.001 per share ("Common Stock")	GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D	2026-10-01	P	Purchase	5517000	Not stated (see footnotes)	15,541,909	1 day	Filed terms security Title: Common Stock, par value $0.001 per share ("Common Stock") transaction Date: 2026-10-01 deemed Execution Date: transaction Form Type: 4 transaction Code: P equity Swap Involved: 0 transaction Timeliness: transaction Shares: 5517000 id: F2 transaction Acquired Disposed Code: A shares Owned Following Transaction: 15541909 direct Or Indirect Ownership: I nature Of Ownership: See footnote id: F1
Common Stock Purchase Warrant (derivative)	GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D	2026-10-01	P	Purchase	7546766	Not stated (see footnotes)	7,546,766	1 day	Filed terms security Title: Common Stock Purchase Warrant conversion Or Exercise Price: 3.5 id: F3 transaction Date: 2026-10-01 deemed Execution Date: transaction Form Type: 4 transaction Code: P equity Swap Involved: 0 transaction Timeliness: transaction Shares: 7546766 id: F2 transaction Acquired Disposed Code: A id: F4 id: F5 underlying Security Title: Common Stock underlying Security Shares: 7546766 shares Owned Following Transaction: 7546766 direct Or Indirect Ownership: I nature Of Ownership: See footnote id: F1

Common Stock, par value $0.001 per share ("Common Stock")

Owner: GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D
Date: 2026-10-01
Code: P
Action: Purchase
Quantity: 5517000
Price: Not stated (see footnotes)
Following holdings: 15,541,909
Reporting delay: 1 day
Filed terms and references: Filed terms
security Title: Common Stock, par value $0.001 per share ("Common Stock")
transaction Date: 2026-10-01
deemed Execution Date:
transaction Form Type: 4
transaction Code: P
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 5517000
id: F2
transaction Acquired Disposed Code: A
shares Owned Following Transaction: 15541909
direct Or Indirect Ownership: I
nature Of Ownership: See footnote
id: F1

Common Stock Purchase Warrant (derivative)

Owner: GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D
Date: 2026-10-01
Code: P
Action: Purchase
Quantity: 7546766
Price: Not stated (see footnotes)
Following holdings: 7,546,766
Reporting delay: 1 day
Filed terms and references: Filed terms
security Title: Common Stock Purchase Warrant
conversion Or Exercise Price: 3.5
id: F3
transaction Date: 2026-10-01
deemed Execution Date:
transaction Form Type: 4
transaction Code: P
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 7546766
id: F2
transaction Acquired Disposed Code: A
id: F4
id: F5
underlying Security Title: Common Stock
underlying Security Shares: 7546766
shares Owned Following Transaction: 7546766
direct Or Indirect Ownership: I
nature Of Ownership: See footnote
id: F1

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
GordonMD Global Investments LP: 10% owner.
GordonMD Long Biased Master Fund LP: 10% owner.
GordonMD Long Biased GP LLC: 10% owner.
Gordon Craig D: 10% owner.
F1: The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
F2: The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90.
F3: Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant.
F4: The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the "Charter Amendment") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the "Charter Amendment Effective Date").
F5: The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma.

Original sources

SEC ownership filing

Prepared automatically from public filing data. Report a correction.

Security

Owner

Date

Code

Action

Quantity

Price

Following holdings

Reporting delay

Filed terms and references

Common Stock, par value $0.001 per share ("Common Stock")

GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D

2026-10-01

Purchase

5517000

Not stated (see footnotes)

15,541,909

1 day

Filed terms

security Title: Common Stock, par value $0.001 per share ("Common Stock")
transaction Date: 2026-10-01
deemed Execution Date:
transaction Form Type: 4
transaction Code: P
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 5517000
id: F2
transaction Acquired Disposed Code: A
shares Owned Following Transaction: 15541909
direct Or Indirect Ownership: I
nature Of Ownership: See footnote
id: F1

Common Stock Purchase Warrant (derivative)

GordonMD Global Investments LP; GordonMD Long Biased Master Fund LP; GordonMD Long Biased GP LLC; Gordon Craig D

2026-10-01

Purchase

7546766

Not stated (see footnotes)

7,546,766

1 day

Filed terms

security Title: Common Stock Purchase Warrant
conversion Or Exercise Price: 3.5
id: F3
transaction Date: 2026-10-01
deemed Execution Date:
transaction Form Type: 4
transaction Code: P
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 7546766
id: F2
transaction Acquired Disposed Code: A
id: F4
id: F5
underlying Security Title: Common Stock
underlying Security Shares: 7546766
shares Owned Following Transaction: 7546766
direct Or Indirect Ownership: I
nature Of Ownership: See footnote
id: F1

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.

GordonMD Global Investments LP: 10% owner.

GordonMD Long Biased Master Fund LP: 10% owner.

GordonMD Long Biased GP LLC: 10% owner.

Gordon Craig D: 10% owner.

F1: The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

F2: The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90.

F3: Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant.

F4: The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the "Charter Amendment") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the "Charter Amendment Effective Date").

F5: The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma.